Carbamylated erythropoietin to treat neuronal injury: new development strategies - PubMed (original) (raw)
Review
Carbamylated erythropoietin to treat neuronal injury: new development strategies
Paul A Lapchak. Expert Opin Investig Drugs. 2008 Aug.
Erratum in
- Expert Opin Investig Drugs. 2008 Sep;17(9):1403
Abstract
Background: Carbamylated erythropoietin (CEPO) is a modified erythropoietin molecule not affecting hematocrit. It is a potentially important pharmacological agent that may be applied to the treatment of several diseases affecting central and peripheral system neurons.
Objective: Carbamylated erythropoietin is a prime candidate for development because of its potent cell survival and function enhancing effects. This article reviews the preclinical development profile of CEPO in animal models to determine whether further clinical development is justified.
Methods: The review spans a detailed analysis of patents and scientific publications related to CEPO in animal models.
Results/conclusions: Use of CEPO in treating diseases such as stroke and traumatic brain and spinal cord injuries is important because these conditions affect millions of patients every year. Extensive preclinical studies support further clinical studies of CEPO for acute ischemic stroke. However, further studies are required for testing CEPO in patients with many other indications.
Similar articles
- Effects of posttraumatic carbamylated erythropoietin therapy on reducing lesion volume and hippocampal cell loss, enhancing angiogenesis and neurogenesis, and improving functional outcome in rats following traumatic brain injury.
Xiong Y, Mahmood A, Zhang Y, Meng Y, Zhang ZG, Qu C, Sager TN, Chopp M. Xiong Y, et al. J Neurosurg. 2011 Feb;114(2):549-59. doi: 10.3171/2010.10.JNS10925. Epub 2010 Nov 12. J Neurosurg. 2011. PMID: 21073254 Free PMC article. - Treatment of traumatic brain injury in rats with erythropoietin and carbamylated erythropoietin.
Mahmood A, Lu D, Qu C, Goussev A, Zhang ZG, Lu C, Chopp M. Mahmood A, et al. J Neurosurg. 2007 Aug;107(2):392-7. doi: 10.3171/JNS-07/08/0392. J Neurosurg. 2007. PMID: 17695395 - Post-ischemic treatment with erythropoietin or carbamylated erythropoietin reduces infarction and improves neurological outcome in a rat model of focal cerebral ischemia.
Wang Y, Zhang ZG, Rhodes K, Renzi M, Zhang RL, Kapke A, Lu M, Pool C, Heavner G, Chopp M. Wang Y, et al. Br J Pharmacol. 2007 Aug;151(8):1377-84. doi: 10.1038/sj.bjp.0707285. Epub 2007 Jul 2. Br J Pharmacol. 2007. PMID: 17603558 Free PMC article. - The use of erythropoietin and its derivatives to treat spinal cord injury.
Mofidi A, Bader A, Pavlica S. Mofidi A, et al. Mini Rev Med Chem. 2011 Aug;11(9):763-70. doi: 10.2174/138955711796355267. Mini Rev Med Chem. 2011. PMID: 21707531 Review. - The nasal route as a potential pathway for delivery of erythropoietin in the treatment of acute ischemic stroke in humans.
Garcia-Rodriguez JC, Sosa-Teste I. Garcia-Rodriguez JC, et al. ScientificWorldJournal. 2009 Sep 15;9:970-81. doi: 10.1100/tsw.2009.103. ScientificWorldJournal. 2009. PMID: 19768354 Free PMC article. Review.
Cited by
- Effects of posttraumatic carbamylated erythropoietin therapy on reducing lesion volume and hippocampal cell loss, enhancing angiogenesis and neurogenesis, and improving functional outcome in rats following traumatic brain injury.
Xiong Y, Mahmood A, Zhang Y, Meng Y, Zhang ZG, Qu C, Sager TN, Chopp M. Xiong Y, et al. J Neurosurg. 2011 Feb;114(2):549-59. doi: 10.3171/2010.10.JNS10925. Epub 2010 Nov 12. J Neurosurg. 2011. PMID: 21073254 Free PMC article. - Carbamylated Erythropoietin: A Prospective Drug Candidate for Neuroprotection.
Chen J, Yang Z, Zhang X. Chen J, et al. Biochem Insights. 2016 Feb 4;8(Suppl 1):25-9. doi: 10.4137/BCI.S30753. eCollection 2015. Biochem Insights. 2016. PMID: 26862298 Free PMC article. Review. - Multifunctional drugs for head injury.
Vink R, Nimmo AJ. Vink R, et al. Neurotherapeutics. 2009 Jan;6(1):28-42. doi: 10.1016/j.nurt.2008.10.036. Neurotherapeutics. 2009. PMID: 19110197 Free PMC article. Review. - Neurorestorative treatments for traumatic brain injury.
Xiong Y, Mahmood A, Chopp M. Xiong Y, et al. Discov Med. 2010 Nov;10(54):434-42. Discov Med. 2010. PMID: 21122475 Free PMC article. Review. - Insight of brain degenerative protein modifications in the pathology of neurodegeneration and dementia by proteomic profiling.
Adav SS, Sze SK. Adav SS, et al. Mol Brain. 2016 Nov 3;9(1):92. doi: 10.1186/s13041-016-0272-9. Mol Brain. 2016. PMID: 27809929 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical